IL123563A - Pharmaceutical formulations comprising amoxycillin and clavulanate in a weight ratio between 14:1 and 16:1 inclusive - Google Patents

Pharmaceutical formulations comprising amoxycillin and clavulanate in a weight ratio between 14:1 and 16:1 inclusive

Info

Publication number: IL123563A
Authority: IL; Israel
Prior art keywords: amoxycillin; clavulanate; formulation; ratio; inclusive
Prior art date: 1995-09-07

Application number

IL12356396A

Other languages

English (en)

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-09-07

Filing date

1996-09-05

Publication date

2002-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21705455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL123563(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-09-05 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2002-02-10 Publication of IL123563A publication Critical patent/IL123563A/en

Links

LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 title claims abstract description 70
229960003022 amoxicillin Drugs 0.000 title claims abstract description 62
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 title claims abstract description 62
HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 title claims abstract description 44
HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 title claims abstract description 44
229940090805 clavulanate Drugs 0.000 title claims abstract description 39
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
239000000203 mixture Substances 0.000 claims description 43
238000009472 formulation Methods 0.000 claims description 35
239000000725 suspension Substances 0.000 claims description 15
ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 11
208000015181 infectious disease Diseases 0.000 claims description 9
238000011282 treatment Methods 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 8
238000000034 method Methods 0.000 claims description 7
239000000843 powder Substances 0.000 claims description 7
239000004615 ingredient Substances 0.000 claims description 5
230000009798 acute exacerbation Effects 0.000 claims description 3
206010006451 bronchitis Diseases 0.000 claims description 3
201000009890 sinusitis Diseases 0.000 claims description 3
206010033078 Otitis media Diseases 0.000 claims description 2
101000605827 Homo sapiens Pinin Proteins 0.000 claims 3
102100038374 Pinin Human genes 0.000 claims 3
METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims 3
METQSPRSQINEEU-OLKMEILKSA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3C3C4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-OLKMEILKSA-N 0.000 claims 3
206010035664 Pneumonia Diseases 0.000 claims 1
210000004072 lung Anatomy 0.000 description 15
241001465754 Metazoa Species 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
239000006188 syrup Substances 0.000 description 8
235000020357 syrup Nutrition 0.000 description 8
239000000243 solution Substances 0.000 description 7
241000193998 Streptococcus pneumoniae Species 0.000 description 6
229940031000 streptococcus pneumoniae Drugs 0.000 description 6
239000002253 acid Substances 0.000 description 5
229960003324 clavulanic acid Drugs 0.000 description 5
238000002156 mixing Methods 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
239000000470 constituent Substances 0.000 description 4
239000000796 flavoring agent Substances 0.000 description 4
235000019634 flavors Nutrition 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
235000012239 silicon dioxide Nutrition 0.000 description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
206010057190 Respiratory tract infections Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
239000011591 potassium Substances 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000007916 tablet composition Substances 0.000 description 3
108010011485 Aspartame Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
208000009362 Pneumococcal Pneumonia Diseases 0.000 description 2
206010035728 Pneumonia pneumococcal Diseases 0.000 description 2
241000700159 Rattus Species 0.000 description 2
239000011149 active material Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
239000000605 aspartame Substances 0.000 description 2
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
229960003438 aspartame Drugs 0.000 description 2
235000010357 aspartame Nutrition 0.000 description 2
239000004067 bulking agent Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000002274 desiccant Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000002054 inoculum Substances 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
229940056360 penicillin g Drugs 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000008261 resistance mechanism Effects 0.000 description 2
208000020029 respiratory tract infectious disease Diseases 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
229940080313 sodium starch Drugs 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
208000022218 streptococcal pneumonia Diseases 0.000 description 2
239000001384 succinic acid Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
229920001285 xanthan gum Polymers 0.000 description 2
229920001817 Agar Polymers 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
244000287680 Garcinia dulcis Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
240000008790 Musa x paradisiaca Species 0.000 description 1
235000018290 Musa x paradisiaca Nutrition 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
235000011034 Rubus glaucus Nutrition 0.000 description 1
244000235659 Rubus idaeus Species 0.000 description 1
235000009122 Rubus idaeus Nutrition 0.000 description 1
239000008272 agar Substances 0.000 description 1
229960004920 amoxicillin trihydrate Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
239000003782 beta lactam antibiotic agent Substances 0.000 description 1
239000003781 beta lactamase inhibitor Substances 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
239000008358 core component Substances 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
235000020375 flavoured syrup Nutrition 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000006916 nutrient agar Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
238000009490 roller compaction Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
239000002132 β-lactam antibiotic Substances 0.000 description 1
229940124586 β-lactam antibiotics Drugs 0.000 description 1
229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

IL12356396A 1995-09-07 1996-09-05 Pharmaceutical formulations comprising amoxycillin and clavulanate in a weight ratio between 14:1 and 16:1 inclusive IL123563A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US335395P	1995-09-07	1995-09-07
PCT/US1996/014554 WO1997009042A1 (en)	1995-09-07	1996-09-05	Pharmaceutical formulation

Publications (1)

Publication Number	Publication Date
IL123563A true IL123563A (en)	2002-02-10

Family

ID=21705455

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12356396A IL123563A (en)	1995-09-07	1996-09-05	Pharmaceutical formulations comprising amoxycillin and clavulanate in a weight ratio between 14:1 and 16:1 inclusive

Country Status (28)

Country	Link
US (3)	US6726908B2 (cs)
EP (3)	EP1147771A1 (cs)
JP (1)	JP3501289B2 (cs)
KR (1)	KR100495585B1 (cs)
CN (1)	CN1289084C (cs)
AR (1)	AR004510A1 (cs)
AT (1)	ATE208618T1 (cs)
AU (1)	AU711441B2 (cs)
BR (1)	BR9610396A (cs)
CA (1)	CA2231194C (cs)
CO (1)	CO4750658A1 (cs)
CY (1)	CY2359B1 (cs)
CZ (1)	CZ299595B6 (cs)
DE (1)	DE69617036T2 (cs)
DK (1)	DK0862431T3 (cs)
ES (1)	ES2165997T3 (cs)
HK (1)	HK1043042A1 (cs)
HU (1)	HUP9901437A3 (cs)
IL (1)	IL123563A (cs)
NO (1)	NO314831B1 (cs)
NZ (3)	NZ337247A (cs)
PL (1)	PL325411A1 (cs)
PT (1)	PT862431E (cs)
SI (1)	SI0862431T1 (cs)
TR (1)	TR199800415T1 (cs)
TW (1)	TW501926B (cs)
WO (1)	WO1997009042A1 (cs)
ZA (1)	ZA967546B (cs)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030109503A1 (en) *	1995-06-06	2003-06-12	Smithkline Beecham P.L.C.	Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
DK0862431T3 (da)	1995-09-07	2002-03-11	Smithkline Beecham Plc	Anvendelse af pædiatrisk farmaceutisk formulering omfattende amoxycillin og clavulanat
GB9617780D0 (en) *	1996-08-24	1996-10-02	Smithkline Beecham Plc	Method of treatment
US6294199B1 (en)	1999-04-13	2001-09-25	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising administering amoxycillin
IL145580A0 (en) *	1999-04-13	2002-11-10	Beecham Pharm Pte Ltd	A modified release pharmaceutical composition comprising amoxycillin and potassium clavulanate
GB2365337A (en) *	1999-04-13	2002-02-20	Beecham Pharma	Amoxycillin and potassium clavulanate high dosage regimen
US6878386B1 (en)	1999-04-13	2005-04-12	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en) *	1999-04-13	2007-07-31	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection
WO2001000177A1 (en) *	1999-06-29	2001-01-04	Micio Pharma Chemical Aktiengesellschaft	Retard formulation of amoxicillin for oral administration
US7985420B2 (en)	2000-04-28	2011-07-26	Reckitt Benckiser Inc.	Sustained release of guaifenesin combination drugs
US6955821B2 (en)	2000-04-28	2005-10-18	Adams Laboratories, Inc.	Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en)	2000-04-28	2011-09-06	Reckitt Benckiser Inc.	Sustained release of guaifenesin combination drugs
US7838032B2 (en)	2000-04-28	2010-11-23	Reckitt Benckiser Inc.	Sustained release of guaifenesin
US6756057B2 (en)	2000-10-12	2004-06-29	Beecham Pharmaceuticals (Pte) Limited	Amoxicillin and potassium clavulanate dosage form
AU2001292185A1 (en)	2000-10-12	2002-04-22	Beecham Pharmaceuticals (Pte) Limited	Formulation containing amoxicillin
JP4732696B2 (ja)	2002-04-09	2011-07-27	フラメル・テクノロジー	活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
KR100456833B1 (ko) *	2002-08-01	2004-11-10	주식회사 대웅	아목시실린 및 클라불라네이트를 함유하는 유핵정
TR200909787A2 (tr)	2009-12-25	2011-07-21	Bi̇lgi̇ç Mahmut	Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
US8614315B2 (en)	2009-12-25	2013-12-24	Mahmut Bilgic	Cefdinir and cefixime formulations and uses thereof
TR201000686A1 (tr)	2010-01-29	2011-08-22	B�Lg�� Mahmut	Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000687A1 (tr)	2010-01-29	2011-08-22	Bi̇lgi̇ç Mahmut	Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
TR201000688A2 (tr)	2010-01-29	2011-08-22	B�Lg�� Mahmut	Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
WO2013057569A2 (en)	2011-10-19	2013-04-25	Micro Labs Limited	Extended release pharmaceutical composition containing amoxicillin and clavulanic acid
BR112014016850A8 (pt) *	2012-01-10	2017-07-04	Hoberman Alejandro	composição líquida para o tratamento de otite media pediátrica, suspensão oral pediátrica, método de tratamento de otite média pediátrica em pacientes com menos de 24 meses de idade e método de tratamento de haemophilus influenzae, e moraxella catarrhalis produtoras de beta-lactamase em pacientes pediátricos com menos de 24 meses de idade
WO2013173808A2 (en) *	2012-05-17	2013-11-21	Michael Spector	Methods for use of lower dose compositions of amoxicillin and clavulanate potassium and devices for use
WO2013173803A2 (en) *	2012-05-17	2013-11-21	Michael Spector	Formulations of amoxicillin and clavulanate potassium and methods for using same
GB201506755D0 (en)	2015-04-21	2015-06-03	Reckitt Benckiser Llc	Novel pharmaceutical formulation
EP3364955B1 (en)	2015-10-09	2022-04-20	RB Health (US) LLC	Pharmaceutical formulation
KR20240109533A (ko) *	2023-01-04	2024-07-11	주식회사 종근당	테노포비르 알라페나미드 또는 이의 약제학적으로 허용가능한 염을 포함하는 안정성이 향상된 약제학적 조성물

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE41109B1 (en) *	1974-04-20	1979-10-24	Beecham Group Ltd	Novel -lactam antibiotic from streptomyces clavuligerus
JO984B1 (en)	1977-10-11	1979-12-01	بيتشام غروب ليمتد	A dry pharmaceutical compound with a suitable dosage unit for oral administration
IL58461A0 (en)	1978-10-27	1980-01-31	Beecham Group Ltd	Intramammary compositions comprising a clavulanic acid salt
NZ198241A (en) *	1980-09-27	1983-12-16	Beecham Group Ltd	Tablet containing amoxycillin and potassium clavulanate
EP0080862B1 (en) *	1981-12-02	1985-09-25	Beecham Group Plc	Pharmaceutical formulation comprising beta-lactam antibiotics
US4673637A (en)	1984-04-23	1987-06-16	Hyman Edward S	Method for detecting bacteria in urine and for treating rheumatoid arthritis, essential hypertension and other diseases associated with bacteriuria
ES2061623T3 (es)	1987-03-02	1994-12-16	Brocades Pharma Bv	Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
US5114929A (en)	1989-03-21	1992-05-19	Beecham Group P.L.C.	Pharmaceutical formulation
GB8909793D0 (en)	1989-04-28	1989-06-14	Beecham Group Plc	Pharmaceutical formulation
KR910009271B1 (ko)	1989-06-20	1991-11-08	김영설	1,1-디옥소페닐실라노일 옥시메틸 D-6-[α-(메틸렌아미노)페닐-아세트아미도]-페니실라네이트와 그의 파라-톨루엔술폰산염
US5814337A (en)	1992-10-07	1998-09-29	Beecham Group Plc	Pharmaceutical formulation
GB9007945D0 (en) *	1990-04-07	1990-06-06	Beecham Group Plc	Pharmaceutical formulation
GB9109862D0 (en)	1991-05-08	1991-07-03	Beecham Lab Sa	Pharmaceutical formulations
GB9114950D0 (en)	1991-07-11	1991-08-28	Smithkline Beecham Plc	Pharmaceutical formulation
EP1034784A3 (en) *	1993-01-22	2001-06-27	Smithkline Beecham Plc	Pharmaceutical formulations containing clavulanic acid and an antibacterial agent
GB9311030D0 (en)	1993-05-28	1993-07-14	Smithkline Beecham Corp	Pharmaceutical formulations
IL109770A0 (en) *	1993-05-29	1994-11-28	Smithkline Beecham Corp	Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9405856D0 (en)	1994-03-24	1994-05-11	Smithkline Beecham Plc	Pharmaceutical formulation
GB9407386D0 (en)	1994-04-14	1994-06-08	Smithkline Beecham Plc	Pharmaceutical formulation
GB9408117D0 (en)	1994-04-23	1994-06-15	Smithkline Beecham Corp	Pharmaceutical formulations
ITMI941169A1 (it)	1994-06-06	1995-12-06	Smithkline Beecham Farma	Formulazioni farmaceutiche
US5567439A (en)	1994-06-14	1996-10-22	Fuisz Technologies Ltd.	Delivery of controlled-release systems(s)
GB9416599D0 (en)	1994-08-17	1994-10-12	Smithkline Beecham Plc	Pharmaceutical formulation
GB9416600D0 (en)	1994-08-17	1994-10-12	Smithkline Beecham Plc	Pharmaceutical formulation
DZ1926A1 (fr)	1994-09-03	2002-02-17	Smithkline Beckman P L C	Formulations pharmaceutiques.
DZ2028A1 (fr)	1995-05-03	2002-10-23	Smithkline Beecham Plc	Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
US5830073A (en)	1995-07-28	1998-11-03	Voss; Brian C.	Bowling lane surfaces
DK0862431T3 (da) *	1995-09-07	2002-03-11	Smithkline Beecham Plc	Anvendelse af pædiatrisk farmaceutisk formulering omfattende amoxycillin og clavulanat
SK110299A3 (en)	1997-02-14	2000-08-14	Smithkline Beecham Lab	Pharmaceutical formulations comprising amoxocyllin and clavulanate, preparation method and use thereof
SE9700885D0 (sv)	1997-03-12	1997-03-12	Astra Ab	New pharmaceutical formulation
ATE286715T1 (de)	1997-03-25	2005-01-15	Takeda Chemical Industries Ltd	Gastrointestinale an der mucosa haftende pharmazeutische zusammensetzung
GB9815532D0 (en)	1998-07-17	1998-09-16	Lek Pharmaceutical & Cvhemical	Pharmaceutical suspension formulation
GB9818927D0 (en)	1998-08-28	1998-10-21	Smithkline Beecham Plc	Pharmaceutical formulation
IL145580A0 (en) *	1999-04-13	2002-11-10	Beecham Pharm Pte Ltd	A modified release pharmaceutical composition comprising amoxycillin and potassium clavulanate

1996
- 1996-09-05 DK DK96930817T patent/DK0862431T3/da active
- 1996-09-05 EP EP01201824A patent/EP1147771A1/en not_active Ceased
- 1996-09-05 KR KR10-1998-0701743A patent/KR100495585B1/ko not_active Ceased
- 1996-09-05 WO PCT/US1996/014554 patent/WO1997009042A1/en not_active Ceased
- 1996-09-05 SI SI9630410T patent/SI0862431T1/xx unknown
- 1996-09-05 BR BR9610396A patent/BR9610396A/pt not_active Application Discontinuation
- 1996-09-05 IL IL12356396A patent/IL123563A/en not_active IP Right Cessation
- 1996-09-05 EP EP96930817A patent/EP0862431B1/en not_active Revoked
- 1996-09-05 NZ NZ337247A patent/NZ337247A/en not_active IP Right Cessation
- 1996-09-05 CN CNB961978791A patent/CN1289084C/zh not_active Expired - Lifetime
- 1996-09-05 PL PL96325411A patent/PL325411A1/xx unknown
- 1996-09-05 EP EP00203970A patent/EP1093812A3/en not_active Ceased
- 1996-09-05 AU AU69733/96A patent/AU711441B2/en not_active Expired
- 1996-09-05 PT PT96930817T patent/PT862431E/pt unknown
- 1996-09-05 CZ CZ0068398A patent/CZ299595B6/cs not_active IP Right Cessation
- 1996-09-05 ES ES96930817T patent/ES2165997T3/es not_active Expired - Lifetime
- 1996-09-05 HU HU9901437A patent/HUP9901437A3/hu not_active Application Discontinuation
- 1996-09-05 CA CA002231194A patent/CA2231194C/en not_active Expired - Lifetime
- 1996-09-05 AR ARP960104241A patent/AR004510A1/es not_active Application Discontinuation
- 1996-09-05 NZ NZ318282A patent/NZ318282A/xx not_active IP Right Cessation
- 1996-09-05 TR TR1998/00415T patent/TR199800415T1/xx unknown
- 1996-09-05 AT AT96930817T patent/ATE208618T1/de not_active IP Right Cessation
- 1996-09-05 DE DE69617036T patent/DE69617036T2/de not_active Revoked
- 1996-09-05 JP JP51146197A patent/JP3501289B2/ja not_active Expired - Lifetime
- 1996-09-06 CO CO96047585A patent/CO4750658A1/es unknown
- 1996-09-06 ZA ZA9607546A patent/ZA967546B/xx unknown
- 1996-10-16 TW TW085110884A patent/TW501926B/zh not_active IP Right Cessation
1997
- 1997-10-27 US US08/722,259 patent/US6726908B2/en not_active Expired - Lifetime
1998
- 1998-03-06 NO NO19981008A patent/NO314831B1/no not_active IP Right Cessation
1999
- 1999-03-02 HK HK02102227.9A patent/HK1043042A1/en unknown
- 1999-08-13 NZ NZ337246A patent/NZ337246A/xx not_active IP Right Cessation
2001
- 2001-02-20 US US09/788,948 patent/US20010038838A1/en not_active Abandoned
2003
- 2003-05-07 CY CY0300039A patent/CY2359B1/xx unknown
- 2003-11-21 US US10/719,211 patent/US20050261267A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1015701A1 (en)	1999-10-22
EP1093812A3 (en)	2001-06-06
CA2231194C (en)	2004-07-20
TR199800415T1 (en)	1998-05-21
CA2231194A1 (en)	1997-03-13
NZ318282A (en)	2000-01-28
CN1289084C (zh)	2006-12-13
NO981008L (no)	1998-05-06
NO981008D0 (no)	1998-03-06
HK1043042A1 (en)	2002-09-06
US20010038838A1 (en)	2001-11-08
JPH11512398A (ja)	1999-10-26
HUP9901437A3 (en)	2000-03-28
WO1997009042A1 (en)	1997-03-13
PL325411A1 (en)	1998-07-20
EP1147771A1 (en)	2001-10-24
NZ337247A (en)	2001-05-25
EP0862431A1 (en)	1998-09-09
AU711441B2 (en)	1999-10-14
MX9801903A (es)	1998-05-31
EP0862431A4 (en)	1999-07-07
NO314831B1 (no)	2003-06-02
AU6973396A (en)	1997-03-27
DE69617036D1 (de)	2001-12-20
KR19990044495A (ko)	1999-06-25
AR004510A1 (es)	1998-12-16
PT862431E (pt)	2002-04-29
CN1200672A (zh)	1998-12-02
ZA967546B (en)	1998-03-06
US20010043926A1 (en)	2001-11-22
KR100495585B1 (ko)	2005-09-09
US6726908B2 (en)	2004-04-27
ATE208618T1 (de)	2001-11-15
BR9610396A (pt)	1999-07-06
DE69617036T2 (de)	2002-07-11
HUP9901437A2 (hu)	1999-09-28
CZ68398A3 (cs)	1998-07-15
EP0862431B1 (en)	2001-11-14
DK0862431T3 (da)	2002-03-11
ES2165997T3 (es)	2002-04-01
TW501926B (en)	2002-09-11
NZ337246A (en)	2000-07-28
CO4750658A1 (es)	1999-03-31
SI0862431T1 (en)	2002-06-30
CY2359B1 (en)	2004-06-04
JP3501289B2 (ja)	2004-03-02
EP1093812A2 (en)	2001-04-25
CZ299595B6 (cs)	2008-09-17
US20050261267A1 (en)	2005-11-24

Legal Events

Date	Code	Title
2002-11-10	KB	Patent renewed
2006-10-30	KB	Patent renewed
2010-12-30	KB	Patent renewed
2017-03-30	EXP	Patent expired

Publication	Publication Date	Title
AU711441B2 (en)	1999-10-14	Pharmaceutical formulation
US6214359B1 (en)	2001-04-10	Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant Streptococcus pneumoniae
AP851A (en)	2000-06-15	Composition comprising amoxycillin and clavulanic acid.
EP1138333B1 (en)	2004-02-25	Medicinal compositions for oral use
WO2001045667A2 (en)	2001-06-28	Water-soluble powders for oral solution and use thereof
HK1036929A (en)	2002-01-25	Amoxycillin and clavulanate containing pharmaceutical formulation
AU4484199A (en)	1999-10-28	Pharmaceutical formulation
MXPA98001903A (en)	1998-10-23	Farmaceut formulation
HK1015701B (en)	2002-09-27	Use of paediatric pharmaceutical formulation comprising amoxycillin and clavulanate
MXPA99001807A (en)	1999-09-20	Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant streptococcus pneumonia
CA2220103C (en)	2006-06-20	Composition comprising amoxycillin and clavulanic acid
EP0843552A2 (en)	1998-05-27	Pharmaceutical formulations